RSV Shot for Babies 2026–2027: Does Yours Need It?

Updated October 15, 2026 | Based on the AAP's 2026–2027 RSV recommendations

RSV season is here, and parents are hearing several different names: RSV vaccine, RSV shot, Beyfortus, Enflonsia, and maternal RSV vaccination.

It's understandable to wonder whether these are different products, whether your newborn needs more than one, and whether the recommendations have changed since last year.

They have changed—but primarily for a particular group of older babies and toddlers.

Here's what the updated AAP guidance means for your family.

What Changed in the AAP's 2026–2027 RSV Recommendations?

The biggest change involves children ages 8 through 19 months entering their second RSV season.

Previously, RSV antibody protection during the second season was recommended for a more limited group of children with certain high-risk conditions.

For 2026–2027, the AAP has expanded eligibility to include additional children who may face a greater risk of serious RSV illness.

The expanded recommendations now include certain children with significant prematurity, heart conditions, lung or neuromuscular problems, and chromosomal conditions, in addition to previously recognized high-risk groups.

What did not change? The AAP continues to recommend RSV protection for infants younger than 8 months during their first RSV season unless they have documented protection from vaccination during pregnancy.

Does My Baby Need an RSV Shot in 2026–2027?

Start with your baby's age and whether you received an RSV vaccine during the pregnancy with this baby.

These recommendations use your child's actual age at the time of immunization, not an age adjusted for prematurity.

There are also special situations in which a pediatrician may recommend infant antibody protection despite maternal vaccination.

What's the Difference Between the RSV Vaccine and the RSV Antibody Shot?

This is one of the most important distinctions for parents.

RSV vaccine during pregnancy: Abrysvo

Pfizer's Abrysvo is a vaccine given during pregnancy. It stimulates the pregnant person's immune system to produce antibodies that can pass through the placenta and help protect the baby after birth.

In most of the continental United States, maternal RSV vaccination is recommended at 32 through 36 weeks of pregnancy, during September through January.

Protection passed from pregnancy lasts approximately the baby's first six months.

RSV antibodies for babies: Beyfortus and Enflonsia

Nirsevimab (Beyfortus) and clesrovimab (Enflonsia) are long-acting monoclonal antibodies.

They are not traditional vaccines. Rather than asking the baby's immune system to make antibodies, they provide protective antibodies directly.

These antibodies help protect against severe RSV disease for at least five months.

Both options protect against RSV, but they work differently.

What If I Received the RSV Vaccine While Pregnant?

Most babies do not need an RSV antibody if their mother received the recommended RSV vaccine during that pregnancy and at least 14 days passed between vaccination and delivery.

That 14-day interval matters because the body needs time to develop and transfer protective antibodies.

If your baby was born fewer than 14 days after maternal vaccination, the AAP recommends an infant RSV antibody.

There are also uncommon situations in which additional antibody protection may be considered, such as:

• Maternal conditions that may limit the immune response to vaccination
• Conditions that reduce antibody transfer across the placenta
• Medical treatments that may remove circulating antibodies from the baby
• Infants with substantially increased risk of severe RSV illness

These decisions should be made with your baby's pediatrician.

Which Babies Qualify for an RSV Shot During Their Second RSV Season?

This is the major 2026–2027 AAP update.

For children ages 8 through 19 months entering their second RSV season, the AAP recommends nirsevimab if they have one of the qualifying high-risk conditions.

Expanded and existing high-risk groups

• Premature birth before 32 weeks: Eligible regardless of whether ongoing medication or respiratory support was required.
• Significant chronic lung disease: Lung disease related to prematurity or other serious newborn conditions when medical support was required during the six months before the second RSV season.
• Hemodynamically significant congenital heart disease: Certain heart defects that cause symptoms or affect heart chamber size.
• Anatomic lung abnormalities or neuromuscular disorders: Conditions that increase the risk of severe RSV disease.
• Severe immune compromise: Conditions or treatments that substantially weaken immune defenses.
• Down syndrome or certain other chromosomal conditions: When associated with increased risk of severe RSV disease.
• Cystic fibrosis: When accompanied by qualifying severe lung disease or weight-for-length below the 10th percentile.
• American Indian or Alaska Native children: Included because of documented disparities in severe RSV disease and hospitalization risk.

The specific medical criteria matter. For example, not every heart murmur, mild lung condition, or chromosomal difference automatically qualifies a child.

If your child has a chronic medical condition, ask their pediatrician whether the expanded 2026–2027 guidance applies.

Can My Baby Get Beyfortus or Enflonsia?

Both products can protect eligible infants younger than 8 months during their first RSV season.

However, they are not interchangeable for every age group.

For the first RSV season, the recommended dose of nirsevimab depends on infant weight. Clesrovimab uses a single fixed dose.

For qualifying high-risk children in their second RSV season, nirsevimab is given as a higher total dose administered in two injections.

Your child's healthcare professional will determine the correct product and dose.

When Should My Baby Receive the RSV Shot?

In most of the continental United States, the RSV antibody administration season runs from October 1 through March 31.

For babies born during this period, the AAP recommends administration within the first week after birth, ideally before discharge from the birth hospital when available.

For eligible babies born outside the season, administration is generally planned shortly before RSV circulation increases, often in October or November.

For high-risk children entering their second season, nirsevimab should be given shortly before that season begins.

RSV activity can differ in Alaska, tropical regions, and other locations. Local public health guidance may modify the usual timing.

How Effective Are RSV Antibody Shots?

According to the AAP, long-acting RSV antibody immunization is expected to reduce the risk of severe RSV disease by approximately 80%.

Protection lasts at least five months, which covers much of a typical RSV season.

Studies from recent RSV seasons have shown meaningful reductions in RSV-related emergency department visits and hospitalizations among immunized infants.

That does not mean an immunized baby can never get RSV.

The primary goal is to reduce the chance of serious lower respiratory tract illness, hospitalization, and complications.

Are RSV Shots Safe for Newborns?

Nirsevimab and clesrovimab have been evaluated for safety and effectiveness in infants.

Possible side effects include:

• Temporary redness or swelling where the injection was given
• Injection-site discomfort
• Rash

Serious allergic reactions are uncommon, but they are possible.

A baby with a history of a serious allergic reaction to an RSV antibody product or one of its components should not receive that product.

RSV antibody immunization can generally be given at the same visit as routine childhood vaccines.

A mild illness does not usually require postponement. Moderate or severe acute illness may warrant delaying administration until the child has improved.

What If My Baby Already Had RSV?

Having RSV previously does not automatically mean your baby no longer needs recommended RSV immunization.

Reinfection is possible, and the AAP advises that prior RSV infection generally should not determine eligibility.

However, RSV antibodies are preventive products—not treatments for an active RSV infection.

If your baby currently has RSV, their pediatrician can advise on medical care and appropriate immunization timing.

What Are the Symptoms of RSV in Babies?

RSV often begins with symptoms resembling an ordinary cold.

You may notice:

• Runny or congested nose
• Cough
• Reduced appetite or feeding
• Fever, although young infants may not have one
• Wheezing or faster breathing
• Increased fussiness or unusual tiredness

In very young babies, RSV may present with poor feeding, reduced activity, or pauses in breathing rather than an obvious cough.

Some infants develop bronchiolitis, an infection affecting the small breathing tubes in the lungs.

How Can I Help Protect My Baby Beyond Immunization?

RSV spreads through respiratory droplets, close contact, and contaminated hands or surfaces.

Additional prevention measures include:

• Wash hands before touching or feeding your baby.
• Ask visitors with respiratory symptoms to postpone visits.
• Avoid exposing your baby to cigarette or vape smoke.
• Clean frequently touched surfaces.
• Limit close contact with people who are actively sick.
• Continue breastfeeding if you are breastfeeding; it offers health benefits but does not replace recommended RSV immunization.

These steps can reduce exposure, but no single measure eliminates RSV risk.

Frequently Asked Questions About RSV Shots in 2026–2027

The Bottom Line: RSV Protection for 2026–2027

The AAP continues to recommend RSV protection for most infants entering their first RSV season. That protection generally comes from either maternal vaccination or an infant RSV antibody.

The important 2026–2027 update is that more high-risk children ages 8 through 19 months now qualify for nirsevimab during their second RSV season.

If your baby is younger than 8 months, confirm how they will be protected. If your older baby has a medical condition, ask whether the expanded recommendations apply.

RSV immunization cannot prevent every infection, but it can substantially reduce the risk of severe illness during a vulnerable stage of life.